Healthcare Companies Are Leaving Money and Autonomy on the Table

Here’s a playbook many healthcare founders know well. Revenue is growing. The product works. Customers are coming back. What happens next? They start pitching venture capitalists.

It’s an understandable instinct. VC funding has been the dominant narrative in startup culture for decades, and healthcare is no exception. But for companies already generating between $5 million and $50 million in annual revenue, reflexively pursuing venture capital is unnecessary, and will cost in ways that don’t show up until it’s too late.

The Real Cost of VC at the Growth Stage

Venture capital isn’t free money – it’s a trade, the terms of which are worth understanding clearly before you sign.

The most visible cost is dilution. When you take on equity investment, you’re giving up a percentage of the company you built. For early-stage startups with no other options, that’s often a reasonable exchange. For a healthcare company already generating meaningful revenue, it’s worth asking whether that exchange is even necessary.

But dilution is just the beginning. VC firms typically require board seats, which means adding voices to your governance structure that come with their own return timelines and priorities. Venture capital operates on a fund cycle, and that clock doesn’t always align with the realities of building a healthcare company, where regulatory approval processes, reimbursement cycles, and market adoption can move on their own schedule entirely.

The result is a structural tension that founders often don’t anticipate: you’ve just brought in partners whose definition of success may look very different from yours.

Healthcare Has Its Own Rhythm

This misalignment hits healthcare companies particularly hard. The industry operates under regulatory complexity that most sectors don’t face. Product development timelines are longer. Compliance requirements shape hiring, operations, and expansion decisions in ways that are difficult to shortcut. A growth strategy built around a VC fund’s exit horizon can push companies to scale faster than the regulatory environment (or their own infrastructure) can safely support.

Healthcare founders who take this path are likely to find that decisions once belonging entirely to the leadership team increasingly require board consensus. Strategic pivots become harder to execute. The company is still growing, but the autonomy that made it worth building in the first place begins to erode.

A Different Path Exists

Growth lending, sometimes called venture debt or non-dilutive growth capital, offers a fundamentally different arrangement. Instead of exchanging equity for capital, companies borrow against their revenue and repay over time. The business keeps its ownership structure intact. The founding team keeps its governance rights. There are no board seat requirements, no conversion rights, no unsolicited involvement in day-to-day operations.

For a healthcare company in the $5 million to $50 million revenue range, this can be a significant advantage. Capital becomes a tool for growth rather than a claim on the future value of the company. Expansion decisions—new markets, new hires, new infrastructure—can be made on the company’s timeline, not an investor’s.

Growth lending also tends to be a faster, more transparent process than equity fundraising. There’s no ambiguous timeline, no series of pitches to partners who may or may not be a fit. Companies that qualify get clear terms and a defined path to funding.

The Question Worth Asking

This is not to say venture capital is wrong for every healthcare company. For pre-revenue startups or businesses that genuinely need strategic guidance and network access alongside capital, VC can be the right fit.

But for healthcare companies that are already generating revenue, already have a functioning team, and already know where they want to go, the question is worth asking: why give up equity and control to get there?

The reflexive answer is that VC is simply how it’s done. The better answer is to understand what you’re trading, and whether there’s a smarter way to fund the next chapter.